Immune Design (NASDAQ:IMDZ) reports 1Q17 loss; Tops Estimate

Immune Design (NASDAQ:IMDZ) reports 1Q17 loss; Tops Estimate


Immune Design Corp (NASDAQ:IMDZ) reported net loss for the first quarter of $ 12.62 million or $ 0.50 per share, compared to loss $ 12.29 million or $ 0.61 per share for the year-ago quarter.

The Seattle, Washington based company recorded Total Revenue for first quarter rose to $ 5.47 million from $ 1.86 million in the same quarter last year.

Analysts polled by Thomson Reuters expected IMDZ to report loss of $ 0.63 per share on revenue of $ 1.88 million for the first quarter.

The first quarter revenue was primarily attributable to $5.2 million in collaboration revenue associated with the Sanofi G103 (HSV2 therapeutic vaccine) collaboration and $0.3 million in product sales to other third parties.

Research and development expenses for the first quarter of 2017 were $14.0 million compared to $10.6 million for the same period in 2016.

Carlos Paya, President and CEO, said: During the first quarter of the year, we were pleased to complete enrollment in the first randomized studies for each of CMB305 and G100, an important milestone for Immune Design.


Comments are closed.